- Home
- KRON vs IPSC Comparison
KRON vs IPSC Comparison
Compare KRON & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- IPSC
- Stock Information
- Founded
- KRON 2017
- IPSC 2019
- Country
- KRON United States
- IPSC United States
- Employees
- KRON N/A
- IPSC N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- KRON Health Care
- IPSC Health Care
- Exchange
- KRON Nasdaq
- IPSC Nasdaq
- Market Cap
- KRON 61.5M
- IPSC 58.1M
- IPO Year
- KRON 2020
- IPSC 2021
- Fundamental
- Price
- KRON $0.83
- IPSC $0.51
- Analyst Decision
- KRON Buy
- IPSC Strong Buy
- Analyst Count
- KRON 3
- IPSC 5
- Target Price
- KRON $1.63
- IPSC $4.67
- AVG Volume (30 Days)
- KRON 165.9K
- IPSC 476.2K
- Earning Date
- KRON 03-18-2025
- IPSC 03-19-2025
- Dividend Yield
- KRON N/A
- IPSC N/A
- EPS Growth
- KRON N/A
- IPSC N/A
- EPS
- KRON N/A
- IPSC N/A
- Revenue
- KRON $9,848,000.00
- IPSC $6,589,000.00
- Revenue This Year
- KRON N/A
- IPSC N/A
- Revenue Next Year
- KRON N/A
- IPSC N/A
- P/E Ratio
- KRON N/A
- IPSC N/A
- Revenue Growth
- KRON 56.62
- IPSC 194.81
- 52 Week Low
- KRON $0.69
- IPSC $0.51
- 52 Week High
- KRON $1.60
- IPSC $4.43
- Technical
- Relative Strength Index (RSI)
- KRON 27.47
- IPSC 30.01
- Support Level
- KRON $0.82
- IPSC $0.54
- Resistance Level
- KRON $0.95
- IPSC $0.59
- Average True Range (ATR)
- KRON 0.06
- IPSC 0.05
- MACD
- KRON -0.01
- IPSC 0.00
- Stochastic Oscillator
- KRON 3.12
- IPSC 0.00
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.